Affimed (AFMD) Competitors

Traws Pharma has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Traws Pharma's return on equity of 112.18% beat Affimed's return on equity.

Traws Pharma has higher revenue and earnings than Affimed.

30.8% of Affimed shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 14.0% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Affimed has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

In the previous week, Traws Pharma had 4 more articles in the media than Affimed. MarketBeat recorded 4 mentions for Traws Pharma and 0 mentions for Affimed. Traws Pharma's average media sentiment score of 0.97 beat Affimed's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media.

Affimed presently has a consensus price target of $0.25, indicating a potential upside of 34.99%. Traws Pharma has a consensus price target of $8.00, indicating a potential upside of 406.33%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than Affimed.

Reviva Pharmaceuticals has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Affimed's return on equity of -193.84% beat Reviva Pharmaceuticals' return on equity.

Reviva Pharmaceuticals has lower revenue, but higher earnings than Affimed.

30.8% of Affimed shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Affimed has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Affimed. MarketBeat recorded 1 mentions for Reviva Pharmaceuticals and 0 mentions for Affimed. Affimed's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score.

Affimed currently has a consensus price target of $0.25, indicating a potential upside of 34.99%. Reviva Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 8,065.93%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Affimed.

Affimed presently has a consensus price target of $0.25, indicating a potential upside of 34.99%. Chemomab Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,433.74%. Given Chemomab Therapeutics' higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Affimed.

In the previous week, Affimed's average media sentiment score of 0.00 equaled Chemomab Therapeutics'average media sentiment score.

Chemomab Therapeutics has lower revenue, but higher earnings than Affimed.

Affimed has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Chemomab Therapeutics has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Chemomab Therapeutics' return on equity of -103.85% beat Affimed's return on equity.

30.8% of Affimed shares are owned by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are owned by institutional investors. 3.8% of Affimed shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Affimed presently has a consensus price target of $0.25, indicating a potential upside of 34.99%. Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 245.91%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Affimed.

In the previous week, Cellectar Biosciences had 4 more articles in the media than Affimed. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Affimed. Affimed's average media sentiment score of 0.00 equaled Cellectar Biosciences'average media sentiment score.

Cellectar Biosciences has lower revenue, but higher earnings than Affimed.

Affimed has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Cellectar Biosciences has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Affimed's return on equity of -193.84% beat Cellectar Biosciences' return on equity.

30.8% of Affimed shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 3.8% of Affimed shares are owned by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.